U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Sickle Cell Acute Painful Episode: Management of an Acute Painful Sickle Cell Episode in Hospital. Manchester (UK): National Institute for Health and Clinical Excellence (NICE); 2012 Jun. (NICE Clinical Guidelines, No. 143.)

Cover of Sickle Cell Acute Painful Episode

Sickle Cell Acute Painful Episode: Management of an Acute Painful Sickle Cell Episode in Hospital.

Show details

8References

  1. Adams-Graves P, Kedar A, Koshy M, et al. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood. 1997;90:2041–6. [PubMed: 9292541]
  2. Adams-Graves P, Ostric EJ, Martin M, et al. Sickle cell hospital unit: A disease-specific model. Journal of Healthcare Management. 2008;53:305–15. [PubMed: 18856136]
  3. Adawy N, Salama E, Eid E, et al. Day case management of painful sickle cell crisis in children using patient controlled analgesia. Egyptian Journal of Anaesthesia. 2005;21:157–62.
  4. Al-Jam’a AH, Al-Dabbous IA, Rafiq MS, et al. Isoxsuprine in the treatment of sickle cell painful crises: A double-blind comparative study with narcotic analgesic. Annals of Saudi Medicine. 1999;19:97–100. [PubMed: 17337943]
  5. Alleyne J, Thomas VJ. The management of sickle cell crisis pain as experienced by patients and their carers. Journal of Advanced Nursing. 1994;19:725–32. [PubMed: 8021394]
  6. Ander DS, Vallee PA. Diagnostic evaluation for infectious etiology of sickle cell pain crisis. American Journal of Emergency Medicine. 1997;15:290–2. [PubMed: 9148990]
  7. Anie KA, Grocott H, White L, Cho G. Patient self-assessment of hospital pain and health related quality of life in adults with sickle cell disease. BMJ. 2012 in press. [PMC free article: PMC3391376] [PubMed: 22761289]
  8. Anie KA, et al. Sickle cell disease: Pain, coping and quality of life in a study of adults in the UK. Br J Health Psychol. 2002 Sep;7(Part 3):331–344. http://www​.ncbi.nlm.nih​.gov/pubmed/12614504 . [PubMed: 12614504]
  9. Audard V, Homs S, Habibi A, et al. Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. Nephrology Dialysis Transplantation. 2010;25:2524–9. [PubMed: 20179008]
  10. Bartolucci P, El MT, Roudot-Thoraval F, et al. A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults. Blood. 2009;114:3742–7. [PubMed: 19717646]
  11. Baumgartner F, Klein S. The presentation and management of the acute abdomen in the patient with sickle-cell anemia. American Surgeon. 1989;55:660–4. [PubMed: 2817619]
  12. Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood. 2000;95:1130–6. [PubMed: 10666181]
  13. Berger E, Saunders N, Wang L, et al. Sickle cell disease in children: differentiating osteomyelitis from vaso-occlusive crisis. Archives of Pediatrics & Adolescent Medicine. 2009;163:251–5. [PubMed: 19255393]
  14. Bernard AW, Lindsell CJ, Venkat A. Derivation of a risk assessment tool for emergency department patients with sickle cell disease. Emergency Medicine Journal. 2008;25:635–9. [PubMed: 18843058]
  15. Booker MJ, Blethyn KL, Wright CJ, et al. Pain management in sickle cell disease. Chronic Illness. 2006;2:39–50. [PubMed: 17175681]
  16. Buchanan GR, Glader BE. Leukocyte counts in children with sickle cell disease. Comparative values in the steady state, vaso-occlusive crisis, and bacterial infection. American Journal of Diseases of Children. 1978;132:396–8. [PubMed: 645659]
  17. Buchanan ID, Woodward M, Reed GW. Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome. Pediatric Blood & Cancer. 2005;45:716–24. [PubMed: 15926170]
  18. Chapman JI, El-Shammaa EN, Bonsu BK. The utility of screening laboratory studies in pediatric patients with sickle cell pain episodes. American Journal of Emergency Medicine. 2004;22:258–63. [PubMed: 15258863]
  19. Finkelstein Y, Schechter T, Garcia-Bournissen F, et al. Is morphine exposure associated with acute chest syndrome in children with vaso-occlusive crisis of sickle cell disease? A 6-year case-crossover study. Clinical Therapeutics. 2007;29:2738–43. [PubMed: 18201591]
  20. Frei-Jones MJ, Field JJ, DeBaun MR. Multi-modal intervention and prospective implementation of standardized sickle cell pain admission orders reduces 30-day readmission rate. Pediatric Blood & Cancer. 2009;53:401–5. [PMC free article: PMC2722244] [PubMed: 19422031]
  21. Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA. 2011;305:893–902. [PMC free article: PMC3403835] [PubMed: 21364138]
  22. Gonzalez ER, Bahal N, Hansen LA, et al. Intermittent injection vs patient-controlled analgesia for sickle cell crisis pain. Comparison in patients in the emergency department. Archives of Internal Medicine. 1991;151:1373–8. [PubMed: 2064488]
  23. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. New England Journal of Medicine. 1994;330:733–7. [PubMed: 8107739]
  24. Grisham JE, Vichinsky EP. Ketorolac versus meperidine in vaso-occlusive crisis: A study of safety and efficacy. International Journal of Pediatric Hematology/Oncology. 1996;3:239–47.
  25. Hardwick WE Jr, Givens TG, Monroe KW, et al. Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatric Emergency Care. 1999;15:179–82. [PubMed: 10389953]
  26. Harris A, Parker N, Barker C. Adults with sickle cell disease: Psychological impact and experience of hospital services. Psychology, Health and Medicine. 1998;3:171–9.
  27. Head CA, Swerdlow P, McDade WA, et al. Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis. American Journal of Hematology. 2010;85:800–2. [PubMed: 20799359]
  28. Jacobson SJ, Kopecky EA, Joshi P, et al. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet. 1997;350:1358–61. [PubMed: 9365450]
  29. Jamison C, Brown HN. A special treatment program for patients with sickle cell crisis. Nursing Economics. 2002;20:126–32. [PubMed: 12077963]
  30. Johnson L. Sickle cell disease patients and patient-controlled analgesia. British Journal of Nursing. 2003;12:144–53. [PubMed: 12610369]
  31. Kind P, Hardman G, Macran S. UK Population norms for EQ-5D. York Centre for Health Economics Discussion Paper. 1999. p. 172.
  32. Kopecky EA, Jacobson S, Joshi P, et al. Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease. Clinical Pharmacology & Therapeutics. 2004;75:140–6. [PubMed: 15001964]
  33. Lattimer L, Haywood C Jr, Lanzkron S, et al. Problematic hospital experiences among adult patients with sickle cell disease. Journal of Health Care for the Poor & Underserved. 2010;21:1114–23. [PMC free article: PMC3240938] [PubMed: 21099065]
  34. Lewing K, Britton K, Debaun M, et al. The impact of parenteral narcotic choice in the development of acute chest syndrome in sickle cell disease. Journal of Pediatric Hematology/Oncology. 2011;33:255–60. [PubMed: 21464764]
  35. Maxwell K, Streetly A, Bevan D. Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study. BMJ. 1999;318:1585–90. [PMC free article: PMC28137] [PubMed: 10364116]
  36. Maxwell K, Streetly A, Bevan D. Experiences of hospital care and treatment-seeking behavior for pain from sickle cell disease: qualitative study. Western Journal of Medicine. 1999;171:306–13. [PMC free article: PMC1308742] [PubMed: 18751193]
  37. Mitchell MB, Lambright WD, Breish R, et al. Meeting the challenge of managing vaso-occlusive crisis. Journal for Healthcare Quality. 2002;24:4–8. [PubMed: 14692181]
  38. Mitchell MJ, Lemanek K, Palermo TM, et al. Parent perspectives on pain management, coping, and family functioning in pediatric sickle cell disease. Clinical Pediatrics. 2007;46:311–9. [PubMed: 17475988]
  39. Montanez A, Berland D. First steps in quality improvement: a pilot program for the management of acute sickle cell pain. Journal of Clinical Outcomes Management. 2002;9:19–27.
  40. Murray N, May A. Painful crises in sickle cell disease--patients’ perspectives. BMJ. 1988;297:452–4. [PMC free article: PMC1833896] [PubMed: 3139140]
  41. Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. JAMA. 2001;286:2099–106. [PubMed: 11694150]
  42. Perlin E, Finke H, Castro O, et al. Enhancement of pain control with ketorolac tromethamine in patients with sickle cell vaso-occlusive crisis. American Journal of Hematology. 1994;46:43–7. [PubMed: 7514356]
  43. Pollack CV Jr, Jorden RC, Kolb JC. Usefulness of empiric chest radiography and urinalysis testing in adults with acute sickle cell pain crisis. Annals of Emergency Medicine. 1991;20:1210–4. [PubMed: 1952307]
  44. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis & Haemostasis. 2007;98:392–6. [PubMed: 17721622]
  45. Raphael JL, Kamdar A, Wang T, et al. Day hospital versus inpatient management of uncomplicated vaso-occlusive crises in children with sickle cell disease. Pediatric Blood & Cancer. 2008;51:398–401. [PubMed: 18300322]
  46. Robieux IC, Kellner JD, Coppes MJ, et al. Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. Pediatric Hematology & Oncology. 1992;9:317–26. [PubMed: 1467165]
  47. Shelley B, Kramer KD, Nash KB. Sickle cell mutual assistance groups and the health services delivery system. J Health Soc Policy. 2011;5:243–59. [PubMed: 10138761]
  48. Strickland OL, Jackson G, Gilead M, et al. Use of focus groups for pain and quality of life assessment in adults with sickle cell disease. Journal of National Black Nurses Association. 2001;12:36–43. [PubMed: 11902019]
  49. Styles LA, Aarsman AJ, Vichinsky EP, et al. Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease. Blood. 2000;96:3276–8. [PubMed: 11050014]
  50. Teuscher T, Von Der Ahe CW, Baillod P, et al. Double-blind randomised clinical trial of pentoxiphyllin in vaso-occlusive sickle cell crisis. Tropical & Geographical Medicine. 1989;41:320–5. [PubMed: 2635446]
  51. van Beers EJ, van Tuijn CF, Nieuwkerk PT, et al. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. American Journal of Hematology. 2007;82:955–60. [PubMed: 17617790]
  52. Wang WC, George SL, Wilimas JA. Transcutaneous electrical nerve stimulation treatment of sickle cell pain crises. Acta Haematologica. 1988;80:99–102. [PubMed: 3138879]
  53. Waters J, Thomas V. Pain from sickle-cell crisis. Nursing Times. 1995;91:29–31. [PubMed: 7731853]
  54. Weiner DL, Hibberd PL, Betit P, et al. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. Journal of the American Medical Association. 2003;289:1136–42. [PubMed: 12622584]
  55. Woods KE, et al. Functional status and well-being in adults with sickle cell disease. J Clin Outcomes Manag. 1997;4(5):15–21.
  56. Wright J, Bareford D, Wright C, et al. Day case management of sickle pain: 3 years experience in a UK sickle cell unit. British Journal of Haematology. 2004;126:878–80. [PubMed: 15352993]
  57. Wright SW, Norris RL, Mitchell TR. Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect. Annals of Emergency Medicine. 1992;21:925–8. [PubMed: 1497158]
  58. Zipursky A, Robieux IC, Brown EJ, et al. Oxygen therapy in sickle cell disease. American Journal of Pediatric Hematology/Oncology. 1992;14:222–8. [PubMed: 1510191]
Copyright © 2012, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

Bookshelf ID: NBK126766
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.4M)

Other titles in this collection

Related NICE guidance and evidence

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...